Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Patients with locally advanced or metastatic breast cancer and with measurable primary breast
tumor will be treated with 70mg docetaxel combined with ketoconazole. Serial tumor biopsies
and plasma samples will be taken for gene expression and proteomics studies to identify
biomarkers that may predict for treatment response.